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lymphedema as Part of routine 
clinical Practice
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Purpose: With improved survivorship, the prevalence of breast cancer-related lymph-
edema (BCRL) continues to increase, leading to impairment of a patients’ quality of life. 
While traditional diagnostic methods are limited by an inability to detect BCRL until clin-
ically apparent, bioimpedance spectroscopy (BIS) has been shown to detect subclinical 
BCRL. The purpose of this study is to evaluate the role of BIS in the early detection of 
BCRL, as well as assessment of response to BCRL treatment.
Methods: A retrospective review of 1,133 patients treated between November 2008 and 
July 2013 at two surgical practices was performed. Eligible patients (n = 326) underwent 
preoperative and postoperative L-Dex measurements. Patients were identified as having 
subclinical lymphedema if they were asymptomatic and the L-Dex score increased 
>10 U above baseline and were monitored following treatment. Patients were stratified 
by lymph node dissection technique [sentinel lymph node biopsy (SLNB) vs. axillary 
lymph node dissection (ALND)] and receipt of BCRL treatment.
results: The average age of the cohort was 56.2 years old, and mean follow-up was 
21.7 months. Of the 326 patients, 210 underwent SLNB and 116 underwent ALND. 
BCRL was identified by L-Dex in 40 patients (12.3%). The cumulative incidence rate of 
subclinical lymphedema was 4.3% for SLNB (n = 9) and 26.7% for ALND (n = 31). Of 
those diagnosed with BCRL, 50% resolved following treatment, 27.5% underwent treat-
ment without resolution, and 22.5% had resolution without treatment. The prevalence of 
persistent, clinical BCRL was 0.5% for SLNB and 8.6% for ALND.
conclusion: This study demonstrates both the feasibility and clinical utility of imple-
menting L-Dex measurements in routine breast cancer care. L-Dex identified patients 
with possible subclinical BCRL and allowed for assessment of response to therapy.
Keywords: breast cancer, lymphedema, bioimpedance, slnB, alnD, Bcrl, Bis, l-Dex
inTrODUcTiOn
Breast cancer represents the most common non-cutaneous cancer among women and as such, treat-
ment paradigms and survivorship strategies continue to evolve (1). Over the past several decades, 
survival for all stages of breast cancer has improved, leading to more long-term survivors, and there-
fore a greater prevalence of chronic sequelae of treatment (2). One complication that can significantly 
TaBle 1 | incidence rates reported in the literature.
reference Diagnostic method Duration of 
follow-up
subjects incidence rates
Haid et al. (7) Self-report
Inter-limb circumference (tape) >2 cm
Clinical examination
ALND mean 
25 months
ALND 140
SLNB 57
ALND 27.1%
SLNB 3.5%
SLNB mean 
18 months
Veronesi et al. (8) Inter-limb circumference (tape) >2 cm 24 months ALND 100
SLNB 100
ALND 6 months 8%
24 months 12%
SLNB 6 months 0%
24 months 0%
Armer et al. (9) Inter-limb circumference (tape) >2 cm Mean 28 months 102 SLNB 22.2%
Self-report ALND 43.3%
Leidenius et al. (10) Self-report
Limb circumference
Clinical examination
36 months ALND 57
SLNB 92
ALND Clinical 13%
Self-report 28%
SLNB Clinical 1%
Self-report 5%
Clark et al. (11) Inter-limb volume (tape) >5% 36 months 188 20.7%
Francis et al. (12) Inter-limb volume and/or circumference (tape) >5% 12 months 155 ALND 47.1%
SLNB 16.8%
Langer et al. (13) Inter-limb circumference (tape) >2 cm
Self-report
ALND mean 
29.5 months
659 ALND 19.1%
SLNB mean 
31.0 months
SLNB 3.5%
Hayes et al. (14) BIS > 3 SD 18 months 287 Point 6 months 10.7%
12 months 8.0%
18 months 14.9%
Cum. 6 months 10.7%
12 months 22.7%
18 months 33.6%
Stout Gergich et al. (15) Limb volume (perometry) >3% change from baseline 18 months 196 21.9%
Johansson and Branje (16) Limb volume (water disp) >5% change from baseline 12 months 292 ALND with radiation 38.7%
Armer and Stewart (6) Limb circumference (tape) >2 cm from baseline and/or 
contralateral limb
60 months 236 12 months 66, 40, 22, and 32%
24 months 81, 56, 36, and 35%
36 months 88, 66, 43, and 39%
60 months 94, 83, 55, and 43%
Limb volume (perometry) >200 ml from baseline and/
or contralateral limb
Limb volume (perometry) >10% from baseline and/or 
contralateral limb
Self-report
2
Laidley and Anglin Impact of L-Dex in Assessing BCRL
Frontiers in Oncology | www.frontiersin.org September 2016 | Volume 6 | Article 192
impair quality of life and has been increasingly  studied is breast 
cancer-related lymphedema (BCRL). BCRL develops due to 
impaired drainage function of the lymphatic system and is pro-
gressive, chronic, costly, and frequently an emotionally devastat-
ing sequelae of breast cancer treatment (3, 4).
Incidence rates from BCRL vary widely with rates of 0–94% 
reported in the literature (Table 1) based on extent and modality 
of locoregional and systemic therapies, diagnostic techniques uti-
lized, and duration of follow-up (5–16). Traditional methods to 
diagnose BCRL include techniques that assess the entire volume 
of the limb, such as circumference measurements, water displace-
ment, and patient self-report. These techniques are limited because 
they require BCRL to be clinically apparent before detection, thus 
lacking sensitivity to detect small changes in extracellular fluid 
(ECF) and subclinical BCRL (5). However, the pathophysiology 
of BCRL suggests that the ECF compartment is the most relevant 
area of concern and studies show it is this compartment that 
changes during the early stages of BCRL. Therefore, assessments 
of the ECF would potentially allow for the detection of subclinical 
BCRL at an earlier time than traditional diagnostic techniques 
that assess the total volume of the limb (17, 18). Bioimpedance 
spectroscopy (BIS) is a technique that assesses the ECF compart-
ment and therefore allows for the subclinical detection of BCRL 
when visible swelling is not apparent. Studies establishing the 
feasibility of BIS in assessing BCRL have demonstrated an earlier 
time to diagnosis than traditional diagnostic modalities (18–20). 
L-Dex is the score reported by the L-Dex U400 unit (ImpediMed 
Limited, Australia) and represents the ECF ratio of the at-risk (or 
affected) limb to the unaffected limb. As ECF accumulates in the 
at-risk limb, the L-Dex score increases. It is therefore a sensitive 
tool for assessing early accumulation of ECF and has demonstrated 
the ability to predict the onset of lymphedema up to 10 months 
FigUre 1 | identification of subclinical lymphedema with l-Dex prior to significant volume increase [adapted from cornish et al. (18)].
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prior to clinical diagnosis (18). Figure 1 shows  published patient 
data for simultaneous L-Dex score and inter-limb volume ratio 
(from circumferential tape measurements) in which the L-Dex 
score increases to a subclinical level approximately 200 days prior 
to the volume ratio (18).
At this time, the importance of early detection and subsequent 
early intervention has been demonstrated with the publication of 
a prospective trial as well as several other studies demonstrating 
improvements in patient outcomes with intervention at earlier 
phases of BCRL (15, 21–26). In 2015, the National Comprehensive 
Cancer Network updated their survivorship guidelines to reflect 
this changing paradigm by noting that part of post-treatment 
follow-up for breast cancer is to “educate, monitor, and refer for 
lymphedema management (27).” L-Dex, by its ability to detect 
subclinical BCRL, represents an innovative strategy for breast 
cancer programs to meet this evidence-based guideline. As 
such, the purpose of this study is to evaluate the clinical utility 
of BIS to detect and monitor the early development of BCRL 
and assessment following BCRL treatment in a large cohort of 
patients evaluated preoperatively and as part of long-term breast 
cancer follow-up.
MaTerials anD MeThODs
A retrospective chart review of 1,133 breast cancer patients treated 
at two surgical practices between November 2008 and July 2013 
was performed with Institutional Review Board approval given 
by the Western Institutional Review Board. Inclusion criteria 
included (1) some form of axillary staging [sentinel lymph node 
biopsy (SLNB) or axillary lymph node dissection (ALND)], 
(2) preoperative L-Dex assessment, and (3) a minimum of two 
subsequent L-Dex assessments. Exclusion criteria included (1) 
bilateral axillary surgery, (2) previously documented diagnosis of 
BCRL, (3) pregnancy, and (4) implanted electronic cardiac device, 
such as a pacemaker. A total of 326 patients meeting such criteria 
were identified and represent the cohort upon which the analysis 
was performed. Surgical technique, axillary sampling technique, 
and L-Dex assessments were available but body mass index (BMI), 
utilization of systemic and radiation therapy was not.
With regard to assessment technique, L-Dex readings 
were taken using the L-Dex U400. Measurements were taken 
with patients lying supine on a non-metallic surface utilizing 
a standardized technique as demonstrated in Figure  2 (19). 
Electrodes were placed on the skin on the midline dorsal surface 
of the wrist at the level of the ulnar styloid process and on the 
skin on the midline anterior surface of the ankle at the level of 
the medial and lateral malleolus bones (9). The L-Dex represents 
the ratio of measured impedance between the at-risk limb and a 
control limb as compared to an equivalent healthy population. The 
linearized L-Dex score allows BIS results to be compared across 
gender, limb dominance, and at-risk limb. When a preoperative 
healthy baseline value has been measured, a change in >10 L-Dex 
units is indicative of the presence of subclinical lymphedema and 
is equivalent to a change in >3 SD of the healthy population (18).
Patients were prospectively monitored preoperatively and 
assessed every 3  months within the first 2  years after surgery, 
in accordance with recommendations from Stout Gergich et al. 
(15), unless recommended otherwise, such as in the case of 
positive assessment for lymphedema. At the first presentation of 
subclinical lymphedema, patients were treated using traditional 
methods (compression sleeve, massage, and/or physical therapy) 
as determined by the practicing physician. Resolution of BCRL 
was defined as a return to within 10 L-Dex units of the preopera-
tive assessment at the end of follow-up.
resUlTs
A total of 326 women met the selection criteria and were evalu-
ated for this study. The mean age of the cohort was 56.2 years old 
with a mean time from preoperative L-Dex assessment to first 
postoperative assessment of 5.4 months. Mean overall follow-up 
was 21.7 months (range: 3.7–54.0 months). For the entire cohort, 
155 patients (47.5%) underwent lumpectomy and 171 (52.5%) 
underwent mastectomy. Two hundred ten patients underwent 
SLNB (64.4%, mean 2.8 nodes) and 116 ALND (35.6%, mean 
12.2 nodes). Table  2 presents patient characteristics, surgical 
technique, and follow-up time.
Breast cancer-related lymphedema status based on L-Dex 
score, treatment, and outcomes, stratified by axillary surgery 
are displayed in Table  3. Of the 326 patients evaluated, the 
cumulative incidence of subclinical BCRL was 12.3% (n =  40) 
with a rate of 4.3% (n =  9) for those undergoing SLNB and 
26.7% (n = 31) for those undergoing ALND. For those under-
going SLNB, the mean time to positive L-Dex assessment was 
TaBle 2 | Patient characteristics.
Total slnB alnD
Total number of subjects 326 210 116
Lumpectomy 155 123 32
Mastectomy 171 87 84
Mean age at baseline (years μ ± σ) 56.2 ± 11.1 55.6 57.5
Mean time to first follow-up (months μ ± σ) 5.4 ± 3.7 5.3 5.7
Mean total follow-up time (months μ ± σ) 21.7 ± 12.2 21.2 22.7
FigUre 2 | Patient undergoing l-Dex U400 measurement.
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5.6 months (2.3–13.6 months) from preoperative assessment and 
mean follow-up from subclinical BCRL diagnosis of 15.7 months 
(0.6–43.7 months). For those undergoing ALND, the mean time 
to positive assessment was 7.5 months (1.3–26.1 months) from 
preoperative assessment and mean follow-up from subclinical 
BCRL diagnosis of 13.4 months (0–18.1 months). Among the 286 
patients not diagnosed with BCRL, 30 patients used prophylactic 
garments when performing perceived high risk activities, such as 
air travel with no patient progressing to BCRL.
Of the 31 patients diagnosed with BCRL who underwent 
treatment (ALND = 24, SLNB = 7), 20 (64.5%) had resolution 
of their BCRL at the end of the study. Nine patients (ALND = 7, 
SLNB =  2) diagnosed with BCRL did not undergo treatment 
with all demonstrating resolution of their BCRL. Seventeen 
SLNB patients and 13 ALND patients, whose L-Dex scores were 
considered normal but showed an increasing trend coincidently 
with self-report of minor symptoms, were treated conservatively 
with a compression sleeve with no patient progressing to BCRL 
at last follow-up. Nine (seven ALND and two SLNB) patients 
had their L-Dex score resolve spontaneously without treatment 
(mean time to positive assessment =  8.2  months, mean time 
from positive assessment to resolution =  4.4  months). Further 
analysis of these subjects shows that for eight of these patients, 
positive assessment occurred within 9.1 months of initial surgery 
(mean = 4.3 months) and was resolved by the next visit (within 
12.6 months, mean 3.0 months).
DiscUssiOn
The results of this study demonstrate several key findings: 
(1)  L-Dex was incorporated into routine breast cancer clinical 
practice and was used as part of routine follow-up care, (2) L-Dex 
scores identified patients in need of BCRL intervention, and 
(3) L-Dex was able to identify an improvement in BCRL following 
treatment. The incidence of BCRL for all patients in the present 
study, regardless of treatment type, was 12.3% (40 patients, mean 
follow-up time = 21.0 months). The incidence rates reported in 
the literature for all cancer treatments varies from 0 to 94%. These 
rates are primarily based on clinically evident BCRL measurable 
by tape circumference or water displacement. The cumulative 
incidence of BCRL in this cohort is lower than that expected 
from the literature (5). Additionally, the end of study incidence 
rates for this analysis (taking into consideration patients whose 
BCRL resolved during the study) have also shown to be much 
lower than chronic incidence rates reported in published studies 
with comparable follow-up durations. One SLNB patient (0.5%) 
(total follow-up time =  15.7  months) and 10 ALND patients 
(8.6%) (mean total follow-up time = 19.6 months) were assessed 
as persistent clinical BCRL at the end of the study. Comparable 
published studies reporting incidence rates with a similar dura-
tion of follow-up range from 3.5 to 16.8% for SLNB and 38.7 to 
47.1% for ALND (see Table 1).
The changing management paradigm for BCRL is based on 
earlier detection and early intervention in order to prevent the 
chronic sequelae of BCRL that are irreversible (3, 5). As such, 
diagnostic modalities such as BIS allow for early detection by 
assessing the ECF and detecting subclinical increases (17, 18). 
Additionally, BIS as a diagnostic technique is objective with mini-
mal inter- and intra-observer variability as compared with other 
techniques (28). With evidence-based guidelines supporting such 
a paradigm (27), trials are underway evaluating this approach; 
however, in the interim, the current data support continued study 
and utilization of early detection and treatment models. A large, 
prospective randomized trial evaluating L-Dex vs. circumference 
measurements with early intervention is currently accruing with 
results expected in the years to come.
The low chronic incidence rates demonstrated in the present 
study suggest that early detection is integral in the management 
of patients at risk of BCRL. By comparing ALND patients moni-
tored with L-Dex technology with a control group monitored 
with tape measurements only, Soran et al. showed the importance 
of using L-Dex technology in early subclinical detection of BCRL 
and early intervention (26). The incidence of clinically apparent 
BCRL for patients in the control group was 36.4 and 4.4% for 
patients monitored with L-Dex technology. This suggests that 
prospective monitoring and treatment of subclinical BCRL using 
L-Dex technology can lead to reduced development of clinical 
BCRL. This study was limited by low patient numbers and lack 
of randomization. Moving forward, a randomized trial (as men-
tioned above) is currently underway, examining the role of BIS in 
allowing for early detection and subsequently early intervention 
with easily applied compression garments in order to prevent 
progression to complex decongestive physiotherapy (29).
Our result demonstrated that a subset of patients had sponta-
neous resolution of BCRL without treatment. This is consistent 
with Kilbreath et  al. who found swelling in the first year after 
breast cancer treatment could possibly be transient due to the 
effects of exercise, surgery, anesthesia, and/or taxane therapy (30). 
TaBle 3 | Patient response to treatment based on l-Dex score.
assessment based on l-Dex Treatment Outcome Total slnB alnD
normal l-Dex values
Normal 256 184 72
Normal (L-Dex trending up) Yes Remain normal 30 17 13
Totals for normal 286 201 85
elevated l-Dex values
BCRL Yes Resolved 20 6 14
BCRL Yes Unresolved 11 1 10
BCRL No Resolved 9 2 7
Totals for BCRL 40 9 31
Total number of subjects 326 210 116
Cumulative incidence of lymphedema (%) 12.3 4.3 26.7
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Currently, there is limited data available to help differentiate those 
patients with transient increases in L-Dex and those who have 
persistent elevations, though future prospective studies will bet-
ter address this.
There are limitations to the current analysis. This was a 
retrospective review and therefore, subject to the limitations of 
such an analysis. While the initial cohort was large, due to the 
small number of events, further data are required to validate these 
findings. Additionally, we were unable to evaluate other factors 
associated with an increased risk of lymphedema (i.e., radiation 
therapy, BMI) due to limits on the data available. Finally, because 
intervention was based on clinician discretion, no cut point 
for beginning intervention could be determined at this time. 
However, this study represents one of the few studies avail-
able that demonstrate the ability to use L-Dex as part of routine 
clinical breast care to identify subclinical BCRL and allow early 
intervention to prevent long-term chronic BCRL.
cOnclUsiOn
The results of this retrospective study demonstrate that L-Dex 
assessments can be incorporated into routine breast cancer 
programs as part of follow-up. This is critically important given 
the recent changes in the NCCN survivorship guidelines for 
post-treatment follow-up care for breast cancer patients estab-
lishing that health-care providers “educate, monitor, and refer for 
lymphedema management.” Additionally, the analyses suggest 
that L-Dex assessments can identify subclinical BCRL and sub-
sequently monitor the return to baseline following conservative 
interventions. Further studies are required to demonstrate the 
long-term benefits of early detection and subsequently early 
intervention predicated upon subclinical detection of BCRL.
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